JENSCARE-B (09877) has released its interim results for the six months ended June 30, 2026, reporting a remarkable 377.7% year-on-year increase in revenue to RMB 64.131 million. The company's adjusted net loss narrowed significantly by 73.2% to RMB 24.586 million, while the loss attributable to owners of the parent company decreased by 71.29% to RMB 48.69 million. The loss per share stood at RMB 0.11.

During the reporting period, the group maintained its strategic focus on the structural heart disease interventional therapy sector, firmly advancing its international expansion plans. By leveraging its diversified portfolio of core product pipelines, the company has continued to drive the clinical application and commercial adoption of its key technologies in global markets.

Following the inauguration of its commercial era in 2025, the group's monetization capabilities have continued to deliver results. Domestic sales of its flagship product, KenValve, have ramped up steadily, while multiple other products have been commercialized through paid clinical implantations across various overseas countries. These factors collectively fueled the substantial revenue growth observed in the period.

With the ongoing expansion of its global registration and commercialization network, the group is well-positioned to sustain rapid revenue growth, laying a robust foundation for long-term sustainable development. For the six-month period, the company achieved revenue of RMB 64.1 million, representing a 377.7% increase year-on-year, with a gross margin of 86.5%. Combined with approximately RMB 9.8 million in other income and gains, total revenue and other income reached approximately RMB 73.9 million, representing a 189.8% growth compared to the same period last year.

The group's global commercialization process continues to accelerate, with revenue scale expanding rapidly and gradually forming a diversified and sustainable growth engine.